P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment
Kazuteru Hatanaka, Satoshi Yuki, Hiroshi Nakatsumi, A. Hosokawa, Michio Nakamura, Osamu Muto, T. Meguro, Ichiro Iwanaga, Yasushi Tsuji, Akinori Sato, K. Eto, Koichi Furukawa, Makoto Onodera, M. Tateyama, Yasuo Takahashi, Masayoshi Dazai, Shigeyuki Yokoyama, Takuya Honda, Hiroyuki Okuda, Masatoshi Kudo, Yuh Sakata, Yoshito Komatsu (2015). P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment. , 26, DOI: https://doi.org/10.1093/annonc/mdv233.266.
